Changeflow GovPing Pharma & Drug Safety Nitrogen-Containing Heterocyclic Compound Paten...
Routine Notice Added Final

Nitrogen-Containing Heterocyclic Compound Patent Application

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Published March 18th, 2026
Detected March 23rd, 2026
Email

Summary

The European Patent Office has published patent application EP4711361A1 concerning a nitrogen-containing heterocyclic compound and its use, filed by Jiangsu Deyuan Pharmaceutical Co., Ltd. The application details compounds represented by formula (II), their stereoisomers, and pharmaceutically acceptable salts.

What changed

European Patent Application EP4711361A1, published on March 18, 2026, by Jiangsu Deyuan Pharmaceutical Co., Ltd., discloses a nitrogen-containing heterocyclic compound and its use. The application specifically covers compounds represented by formula (II), their stereoisomers, and pharmaceutically acceptable salts, with potential applications in pharmaceuticals.

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it is relevant for pharmaceutical companies and drug manufacturers involved in research and development, particularly those working with similar chemical structures. Companies should monitor the patent's prosecution status and consider potential intellectual property implications for their own research and development activities.

Source document (simplified)

← EPO Patent Bulletin

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF

Publication EP4711361A1 Kind: A1 Mar 18, 2026

Applicants

Jiangsu Deyuan Pharmaceutical Co.,Ltd.

Inventors

GAN, Lu, YU, Tao, LIU, Ning, ZHANG, Yang, CHEN, Shuhui

Abstract

A nitrogen-containing heterocyclic compound and the use thereof, and specifically disclosed are a compound as represented by formula (II), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.

IPC Classifications

C07D 401/04 20060101AFI20241122BHEP C07D 491/052 20060101ALI20241122BHEP C07D 471/04 20060101ALI20241122BHEP C07D 413/04 20060101ALI20241122BHEP C07D 519/00 20060101ALI20241122BHEP C07D 498/04 20060101ALI20241122BHEP A61P 9/12 20060101ALI20241122BHEP A61K 31/438 20060101ALI20241122BHEP A61K 31/538 20060101ALI20241122BHEP A61K 31/437 20060101ALI20241122BHEP A61K 31/436 20060101ALI20241122BHEP A61K 31/4375 20060101ALI20241122BHEP A61K 31/4439 20060101ALI20241122BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

Nitrogen-Containing Heterocyclic Compound and Use Thereof

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4711361A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Intellectual Property Protection
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Intellectual Property Drug Development

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.